gemfibrozil has been researched along with Dyslipidemias in 29 studies
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 9.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| "To assess the lipid-modifying and pleiotropic effects of drugs of the statin group (simvastatin and pravastatin) and the fibrate group (gemfibrozil) in dyslipidemia patients." | 9.12 | Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia. ( Doncheva, NI; Nikolov, KV; Vassileva, DP, 2006) |
| " simvastatin and gemfibrozil in type 2 diabetic patients with dyslipidemia in Pakistani population." | 9.11 | Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. ( Amir, K; Ashraf, R; Shaikh, AR, 2005) |
| "Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome." | 7.73 | Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. ( Kovanen, PT; Manninen, V; Mänttäri, M; Tenkanen, L; Virkkunen, H, 2006) |
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 5.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| "To assess the lipid-modifying and pleiotropic effects of drugs of the statin group (simvastatin and pravastatin) and the fibrate group (gemfibrozil) in dyslipidemia patients." | 5.12 | Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia. ( Doncheva, NI; Nikolov, KV; Vassileva, DP, 2006) |
| " simvastatin and gemfibrozil in type 2 diabetic patients with dyslipidemia in Pakistani population." | 5.11 | Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. ( Amir, K; Ashraf, R; Shaikh, AR, 2005) |
| " Of all the medications currently available, the fibric acid derivatives have a cholesterol lowering profile that is most likely to be effective in obese children with the high TG/low HDL phenotype and data from a recently published study of gemfibrozil in children with metabolic syndrome are promising." | 4.89 | Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. ( Jellerson, KD; Kennedy, MJ; Snow, MZ; Zacchetti, ML, 2013) |
| "Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome." | 3.73 | Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. ( Kovanen, PT; Manninen, V; Mänttäri, M; Tenkanen, L; Virkkunen, H, 2006) |
| " An unusual dose-response pattern was observed in that at 6 mg/day CP-778,875 only increased HDL cholesterol by 3% and decreased HDL(2) cholesterol by 24%." | 2.73 | Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. ( Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG, 2008) |
| "Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes." | 2.73 | Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). ( Bloomfield, H; Brousseau, ME; Collins, D; Georgopoulos, A; O'Connor, JJ; Ordovas, JM; Robins, SJ; Schaefer, EJ, 2007) |
| "Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C." | 2.46 | Management of dyslipidemia in people with type 2 diabetes mellitus. ( Dunn, FL, 2010) |
| "Metformin has a greater impact on BMI in responders of metformin compared to nonresponders." | 1.43 | The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin. ( Alizadeh, A; Kashi, Z; Kianmehr, A; Mahrooz, A, 2016) |
| " Patients were stratified according to statin and dosage to identify against-label combination use (e." | 1.38 | Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. ( Alford, JC; Allen, RR; Nair, KV; Saseen, JJ, 2012) |
| "Monotherapy for the treatment of dyslipidemias is commonly insufficient to achieve all lipid targets recommended by current guidelines." | 1.33 | [Drug combinations: statins and fibrates]. ( Xavier, HT, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (55.17) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sashidhara, KV | 3 |
| Kumar, A | 4 |
| Bhatia, G | 6 |
| Khan, MM | 2 |
| Khanna, AK | 3 |
| Saxena, JK | 1 |
| Ghosh, S | 1 |
| Misra, AK | 1 |
| Maurya, RA | 2 |
| Sharma, S | 2 |
| Ahmad, P | 1 |
| Singh, AB | 1 |
| Srivastava, AK | 2 |
| Tripathi, VD | 1 |
| Srivastava, SP | 1 |
| Tamrakar, AK | 1 |
| Kumar, M | 1 |
| Sonkar, R | 2 |
| Palnati, GR | 1 |
| Avula, SR | 1 |
| Awasthi, C | 1 |
| Fruchart, JC | 1 |
| Santos, RD | 1 |
| Hussain, M | 1 |
| Shad, MN | 1 |
| Akhtar, L | 1 |
| Kennedy, MJ | 1 |
| Jellerson, KD | 1 |
| Snow, MZ | 1 |
| Zacchetti, ML | 1 |
| Kashi, Z | 1 |
| Mahrooz, A | 1 |
| Kianmehr, A | 1 |
| Alizadeh, A | 1 |
| Terra, SG | 1 |
| Francone, OL | 1 |
| Contant, CF | 1 |
| Gao, X | 1 |
| Lewin, AJ | 1 |
| Nguyen, TT | 1 |
| Silverberg, MJ | 1 |
| Leyden, W | 1 |
| Hurley, L | 1 |
| Go, AS | 1 |
| Quesenberry, CP | 1 |
| Klein, D | 1 |
| Horberg, MA | 1 |
| Nolan, DP | 1 |
| O'Connor, MB | 1 |
| O'Connor, C | 1 |
| Moriarty, M | 1 |
| O'Leary, A | 1 |
| Bergin, C | 1 |
| Dunn, FL | 1 |
| Amend, KL | 1 |
| Landon, J | 1 |
| Thyagarajan, V | 1 |
| Niemcryk, S | 1 |
| McAfee, A | 1 |
| Alford, JC | 1 |
| Saseen, JJ | 1 |
| Allen, RR | 1 |
| Nair, KV | 1 |
| Shaikh, Q | 1 |
| Kamal, AK | 1 |
| Lee, CY | 1 |
| Huang, KH | 1 |
| Lin, CC | 1 |
| Tsai, TH | 1 |
| Shih, HC | 1 |
| Ashraf, R | 1 |
| Amir, K | 1 |
| Shaikh, AR | 1 |
| Chironi, G | 1 |
| Simon, A | 1 |
| Gariepy, J | 1 |
| Balice, M | 1 |
| Del-Pino, M | 1 |
| Levenson, J | 1 |
| Saseen, J | 1 |
| Tweed, E | 1 |
| Crawford, P | 1 |
| Xavier, HT | 1 |
| Tenkanen, L | 1 |
| Mänttäri, M | 1 |
| Kovanen, PT | 1 |
| Virkkunen, H | 1 |
| Manninen, V | 1 |
| Georgopoulos, A | 1 |
| Bloomfield, H | 1 |
| Collins, D | 1 |
| Brousseau, ME | 1 |
| Ordovas, JM | 1 |
| O'Connor, JJ | 1 |
| Robins, SJ | 1 |
| Schaefer, EJ | 1 |
| Patel, J | 1 |
| Rizzo, M | 1 |
| Berneis, K | 1 |
| Doncheva, NI | 1 |
| Nikolov, KV | 1 |
| Vassileva, DP | 1 |
| Chrysohoou, C | 1 |
| Singh, S | 1 |
6 reviews available for gemfibrozil and Dyslipidemias
| Article | Year |
|---|---|
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib | 2019 |
Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents.
Topics: Adolescent; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fibri | 2013 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ez | 2010 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; D | 2006 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipi | 2007 |
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials a | 2006 |
5 trials available for gemfibrozil and Dyslipidemias
| Article | Year |
|---|---|
Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
Topics: Adult; Aged; Body Mass Index; Body Weight; Dyslipidemias; Female; Gemfibrozil; Humans; Hypoglycemic | 2017 |
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; C-Reactive Protein; Cholesterol, HDL; Diabete | 2008 |
Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gemfibr | 2005 |
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
Topics: Aged; Codon; Diabetes Mellitus; Dyslipidemias; Fatty Acid-Binding Proteins; Gemfibrozil; Genetic Pre | 2007 |
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Topics: Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravast | 2006 |
18 other studies available for gemfibrozil and Dyslipidemias
| Article | Year |
|---|---|
Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases.
Topics: Amines; Animals; Antioxidants; Dyslipidemias; Fluorescence; Heparin; Hydroxyl Radical; Hydroxyquinol | 2009 |
Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents.
Topics: Animals; Antioxidants; Drug Evaluation, Preclinical; Dyslipidemias; Hypolipidemic Agents; Rats; Semi | 2009 |
Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dyslipidemias; Hypoglycemic Agents; Lipid M | 2009 |
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Dyslipidemias; Glycogen Phosphorylase; Hypogl | 2010 |
Novel coumarin derivatives as potential antidyslipidemic agents.
Topics: Coumarins; Dyslipidemias; Humans | 2010 |
Coumarin chalcone fibrates: a new structural class of lipid lowering agents.
Topics: Animals; Chalcones; Coumarins; Dyslipidemias; Male; Molecular Structure; Polyethylene Glycols; Rats; | 2013 |
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Topics: Adult; Atorvastatin; Biological Transport; Blood Glucose; Blood Pressure; Body Mass Index; Cholester | 2016 |
Summaries for patients. Response to cholesterol-lowering drugs in patients with and without HIV infection.
Topics: Anti-HIV Agents; Cholesterol, LDL; Dyslipidemias; Female; Gemfibrozil; HIV Infections; Humans; Hypol | 2009 |
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
Topics: Anti-HIV Agents; Cholesterol, LDL; Cohort Studies; Dyslipidemias; Female; Gemfibrozil; HIV Infection | 2009 |
HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dy | 2010 |
Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Topics: Cohort Studies; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Electronic Health Reco | 2011 |
Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Labeling; Drug Therapy, Combination; Dyslipid | 2012 |
HDL cholesterol--how do I raise my patients good cholesterol?
Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Evidence-Based | 2012 |
A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; H | 2012 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Aci | 2005 |
Clinical inquiries. What are effective medication combinations for dyslipidemia?
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medic | 2006 |
[Drug combinations: statins and fibrates].
Topics: Age Factors; Clofibric Acid; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Ge | 2005 |
Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study.
Topics: Coronary Disease; Double-Blind Method; Dyslipidemias; Follow-Up Studies; Gemfibrozil; Humans; Hypoli | 2006 |